Skip to main content

Gentel Acquires Trademark from Eppendorf

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Gentel Biosciences today said that it has acquired the SilverQuant trademark from Eppendorf, which it will apply to its protein array technology platform.

Madison, Wis.-based Gentel said the acquisition of the trademark complements its other initiatives to grow its market position as a provider of multiplexed proteomic tools.

In 2008, Gentel had acquired from Eppendorf the rights to array-based chromogenic detection technology that uses gold particle-enhanced silver crystal deposition for detection and quantification of arrays. Today, it said that the SilverQuant technology works with the Gentel Proteomics Multi-System, which integrates chromogenic scanning and analysis of arrays at a price comparable to a benchtop ELISA system.

"The SilverQuant name accurately describes our unique chromogenic detection technology as well as its application to protein quantitation," Gentel VP of Commercial Development Dan Clutter said in a statement. "Further, SilverQuant is a strong trademark that adds a valuable intangible asset to the company given its worldwide registration and existing prestige in the life sciences."

Financial terms of the trademark acquisition were not disclosed.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.